Posted on June 24, 2016 by Albin Paul
Government of France Announce plans to invest €670 million euros or ($760.8 million) for Genomics and Personalized Medicine which will see it establish 12 genome sequencing centers and two national centers for genomic expertise and data analysis. The program would initially focus on cancer, diabetes and rare diseases but after 2020 would expand to include common diseases.
This investment by France follows the release on Wednesday of a report by medical experts examining the possibility of France widening access to genetic medicine within 10 years. A key objective in the report for the first 10 years of the programme is to prepare for the integration of genomic medicine into the normal course of patient care in the country, which means sequencing about 235,000 genomes per year by 2020.
Health Minister Marisol Touraine said Investment in the five year initiative will also come from industry. He also expected Companies like Google, Amazon, Apple and Facebook are interested in the growing genomic medicine sector
Several European countries have already begun to integrate genomic medicine into their health systems and there are large scale genomic initiatives in the UK, US and China. China has even recently announced a Precision Medicine Cloud
Filed under: bioinformatics, Genomics, personalized medicine | Tagged: amazon, apple, cloud, facebook, Genomics, genomics cloud, google, personalized medicine | Leave a comment »
Posted on November 17, 2010 by Albin Paul
According to a new report from the Tufts Center for the Study of Drug Development at Tufts University 12 to 50 percent of the drugs companies are developing, depending on the company, involved a personalized medicine approach.
The Tufts report is based on a survey of 25 companies, large and small, to which 16 companies responded, as well as interviews with representatives of 13 companies.
Relatively few drugs are now accompanied by such so-called companion diagnostic tests. They are most common in oncology. The breast cancer drug Herceptin, for instance, is given only to women whose tumors have an abundance of a protein called Her2.
According to the report Other key therapeutic areas in which personalized medicine is making headway include cardiovascular, central nervous system, and immunologic therapies, whereas personalized medicine development is just getting started for metabolic and respiratory therapies, as well as virology.
Filed under: clinical research, Clinical Trial, drug development, drug discoverry, personalized medicine, Pharmacogenomics, Theranostics | Tagged: Drug Development, drug discovery, personalized medicine, theranostics | Leave a comment »
Posted on September 30, 2010 by Albin Paul
The Institute is focused on research that will accelerate IT innovation to advance personalized medicine and the delivery of safe and effective treatments and health care services to patients around the globe. OHSI will work in tandem with academic research centers, focusing on a targeted set of research areas fundamental to the R&D and health care delivery challenges facing health sciences organizations today. Research priorities currently include: artificial intelligence and semantic technology; genomic, genetic and phenotypic data analysis; data mining to support optimization of clinical trials; and predictive algorithms and other technology to advance patient safety and provide advanced decision support at the point of care.Academic institutions interested in collaborating with OHSI in these focus areas should contact OHSI representatives at Oracle http://linkd.in/bXf98c
Oracle starts Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs. This is exiting news and I hope we get to see the participation of Open Source Drug Development Network (OSDD) and initiative by CSIR India earlier supported by Sun Microsystems
Filed under: Drug Safety, genetic medicine, Online Data sharing, open access database, open source, oracle, Oracle Health Sciences Global Business Unit, Patient Safety, personalized medicine, Pharmacogenomics, pharmacovigilance | Tagged: Drug Safety, health sciences global business unit, HSGBU, OHSI, Open Source Drug Development Network, oracle, Oracle Health Science Global Business Unit, Oracle Health Sciences Institute, personalized medicine, Pharmacogenomics, pharmacovigilance, Sun Labs | 1 Comment »